This chapter describes the US record. Read the date along with the answer.
Approval: none for this substance
In the US, BPC-157 has no FDA-approved treatment use in the September 2026 record.
The Food and Drug Administration (FDA), which reviews US medicines, also reported finding no approved product containing it in any country.
That finding rests on the FDA’s search of international medicine records.
Withdrawn means a request was taken back
FDA table · request taken back
A taken-back request gives no permission
Groups had asked FDA to let pharmacies use BPC-157 as a raw ingredient for named patients. They took those requests back. FDA’s page, marked current on April 22, 2026, lists BPC-157 with those taken-back requests.
BPC-157 is outside Category 2, FDA’s group of ingredients flagged for serious possible harm. That does not mean FDA found it safe or gave approval or permission to use it.
FDA gives no date for when the request was taken back and still lists its safety concerns.
As checked in September 2026, US federal rules do not allow a regular pharmacy to make BPC-157 from the raw ingredient for a named patient.
A doctor’s prescription does not replace the ingredient rules: a quality standard, use in an approved medicine, or a place on FDA’s allowed-ingredient list.
The advisory meeting did not supply an approval
In July 2026, FDA staff proposed leaving BPC-157 off the list of raw ingredients allowed for named-patient pharmacy compounding.
No official account of the committee’s voting had been posted by FDA through September 28, 2026.
A committee vote only advises FDA. Changing the ingredient list requires FDA to first publish a proposed rule, ask for public comment and then publish the final rule.
Ask for the current record
If a service says the ingredient list has changed, ask for the published final rule. Check whether it actually adds this ingredient and read the date it takes effect. Ask the doctor or pharmacist to explain any wording you cannot follow.